Source: International Congress 2014 – Markers
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
V. Pinto-Plata, M. Divo, C. Owen, F. Polverino, M. Laucho, B. Celi (Boston, United States Of America). Metabolomic signature in COPD. Plasma and lung tissue comparison identify sphingolipids as potential biomakers. Eur Respir J 2014; 44: Suppl. 58, 577

Member's Comments

No comment yet.

Related content which might interest you: Stable state MR-proadrenomedullin level in COPD patients; a validation study Source: International Congress 2014 – Comorbidities Year: 2014 Role of inflammatory biomarkers in COPD Source: International Congress 2016 – Systemic biomarkers Year: 2016 What is the best biomarker of COPD stability? Source: International Congress 2015 – COPD: chronic disease and comorbidities Year: 2015 Alterations of the soluble proteome of airway epithelial cells in COPD Source: Annual Congress 2013 –New strategies in epigenomic research to study lung diseases (DNA rearrangements, RNA, methylation, proteosome) Year: 2013 A multimarker approach to identify atherosclerosis in COPD Source: International Congress 2014 – Markers Year: 2014 COPD and lung cancer: Prevalence, infradiagnosis, phenotypes and multidimensional characterization Source: International Congress 2016 – Epidemiology and specific subgroups in lung cancer Year: 2016 Gender differences in COPD patients Source: International Congress 2014 – Clinical presentations Year: 2014 Evolution of COPD phenotypes in time - Czech multicentre research database of severe COPD Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016 Features of systemic inflammation in patients with stable COPD Source: International Congress 2014 – COPD: points to ponder Year: 2014 Plasma metabolomic signature in COPD patients: Associations to proteomic profile and clinical outcomes Source: Annual Congress 2013 –COPD mechanisms Year: 2013 Differences in plasma and sputum biomarkers between COPD and COPD-asthma overlap Source: Annual Congress 2013 –Is it really asthma? Year: 2013 What should be part of a comprehensive assessment of COPD? Source: International Congress 2016 – Best abstracts in COPD management Year: 2016 Biomarkers in COPD exacerbation, the role of adiponectin Source: International Congress 2014 – Predictors Year: 2014 Adrenomedullin optimizes mortality prediction in COPD Source: International Congress 2014 – COPD exacerbations Year: 2014 Heterogeneity inside group D COPD patients: About 827 cases Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016 Clustering asthma and COPD provides new evidence for both “British” and “Dutch” hypotheses of COPD development Source: Annual Congress 2013 –Risk factors for COPD and lung function decline Year: 2013 Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level Source: International Congress 2014 – COPD markers Year: 2014 Can red blood cell morphology be an indicator for COPD exacerbations? Source: International Congress 2014 – Markers Year: 2014 Increased circulating alveolar epithelial microparticles in COPD patients Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015 The role of COPD in development of osteoporosis Source: International Congress 2014 – Markers Year: 2014